<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887601</url>
  </required_header>
  <id_info>
    <org_study_id>3134-006</org_study_id>
    <secondary_id>2009_583</secondary_id>
    <nct_id>NCT00887601</nct_id>
  </id_info>
  <brief_title>BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)</brief_title>
  <official_title>A 4-Period, Placebo-Controlled, Crossover Study to Evaluate the Utility and Feasibility of BOLD fMRI and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (Donepezil and MK3134)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate functional magnetic resonance imaging (fMRI) and methods for
      measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving
      drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Difference in number of voxels showing a positive response after treatment with donepezil and placebo</measure>
    <time_frame>3.5 to 4.5 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I: Difference in number of voxels activated for both faces and scenes after treatment with donepezil and placebo</measure>
    <time_frame>3.5 to 4.5 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Number of voxels showing a positive response after varying doses of MK3134 compared to placebo</measure>
    <time_frame>3.5 to 4.5 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Number of voxels activated for both faces and scenes after varying doses of MK3134 compared to placebo</measure>
    <time_frame>3.5 to 4.5 hours after study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part I: Difference in arterial transit time as measured by arterial spin labeling after treatment with donepezil and placebo</measure>
    <time_frame>3.5 to 4.5 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Difference in Pulsatility index after treatment with donepezil and placebo</measure>
    <time_frame>5 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Test-retest reproducibility of the BOLD fMRI and cerebral blood flow measurements in donepezil treated subjects</measure>
    <time_frame>1 to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Change in arterial transit time after treatment with placebo and varying doses of MK3134</measure>
    <time_frame>3.5 to 4.5 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Change in Pulsatility index after treatment with placebo and varying doses of MK3134</measure>
    <time_frame>5 hours after study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Part I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3134</intervention_name>
    <description>Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.</description>
    <arm_group_label>Part I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo capsules only in one of the four treatment periods.</description>
    <arm_group_label>Part I</arm_group_label>
    <arm_group_label>Part II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Single dose 5 mg donepezil capsules in two of the four treatment periods.</description>
    <arm_group_label>Part I</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3134</intervention_name>
    <description>Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods</description>
    <arm_group_label>Part II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a nonsmoker

          -  Subject is in generally good health

          -  Subject has normal (or corrected to normal) vision and hearing

          -  Subject is right-handed

        Exclusion Criteria:

          -  Subject has a history of any illness that would make participation unsafe or would
             make the study results difficult to interpret

          -  Subject has a history of stroke, seizures, or major neurological disorders

          -  Subject has a history of cancer

          -  Subject has permanent cosmetic or metallic implants that would interfere with
             measurements

          -  Subject has a history of sleep apnea

          -  Subject has a history of head injury/trauma
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Nootropic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

